The study was performed while the delta variant was the dominant strain of coronavirus in Israel
A study of 200,000 Israeli adolescents shows that Pfizer's coronavirus vaccine is 93 percent effective in stopping symptoms of Covid-19, and almost as effective in protecting the immune system of the delta variant from the virus, researchers said Wednesday.
The study, conducted by researchers from Israel's health organization Clalit, Harvard University and Boston Children's Hospital, compared 94,354 young people between the ages of 12 and 18 who received the vaccine with the same number of unvaccinated people of the same age group.
The study was performed while the delta variant was the dominant strain of coronavirus in Israel, which led researchers to conclude that the vaccine was as effective in young people against the mutation as against earlier versions.
“Our results show that the BNT162b2 mRNA vaccine was highly effective in the first few weeks after vaccination against both documented infection and symptomatic Covid-19 with the delta variant among adolescents between the ages of 12 and 18 years,” wrote the researchers in a letter to the New England Journal of Medicine, which included the data.
According to the analysis, adolescents who received the vaccine between June 8 and September 14 were 59 percent less likely than those in an unvaccinated control group to contract the coronavirus two weeks after receiving the first dose and 57 percent less likely to show symptoms of Covid-19.
These figures rose to 90 percent and 93 percent respectively a week after the administration of the second dose of the vaccine, according to the study.
The authors noted that the delta variant was responsible for over 95 percent of all infections in Israel during the trial period.